We are excited to continue our journey, and our ongoing commitment to empowering researchers.
International Plant & Animal Genome in San Diego, CA
International Plant & Animal Genome in San Diego, CA
myTXTL – Featured Publications
Please browse some recent publications utilizing targeted sequencing with myTXTL.
Liang, J. et al.. (2022) Directed Evolution of Replication-Competent Double-Stranded DNA Bacteriophage toward New Host Specificity ACS Synthetic Biology 2022 bacteriophage. featured myTXTL
Wandera, K. et al (2022). Anti-CRISPR prediction using deep learning reveals an inhibitor of Cas13b nucleases Molecular Cell 2022 CRISPR technology myTXTL
Wandera, K. et al (2022) Rapidly Characterizing CRISPR-Cas13 Nucleases Using Cell-Free Transcription-Translation Systems Post-Transcriptional Gene Regulation CRISPR technology myTXTL
Lin, P. et al. (2022) Type III CRISPR-based RNA editing for programmable control of SARS-CoV-2 and human coronaviruses Nucleic Acids Research 2022 CRISPR technology, SARS-CoV-2, myTXTL T7 expression Kit myTXTL
Haslinger, K. et al. (2021) Rapid in vitro prototyping of O-methyltransferases for pathway applications in Escherichia coli [featured] Cell Chemical Biology 2021 assay development, featured, protein production myTXTL
Taxiarchi, C. et al. (2021) A genetically encoded anti-CRISPR protein constrains gene drive spread and prevents population suppression Nature Communications 2021 CRISPR technology myTXTL
Khakimzhan, A. et al. (2021) Complex dependence of CRISPR-Cas9 binding strength on guide RNA spacer lengths Physical Biology 2021 CRISPR technology myTXTL
Collins, S. et al. (2021) Sequence-independent RNA sensing and DNA targeting by a split domain CRISPRCas12a gRNA switch Nucleic Acids Research 2021 CRISPR technology myTXTL
Blume, C. et al. A novel ACE2 isoform is expressed in human respiratory epithelia and is upregulated in response to interferons and RNA respiratory virus infection Nature Genetics 2021 SARS-CoV-2, protein production myTXTL
Kato, S. et al., (2021) Phase separation and exclusive protein localizations in compartmentalized cell-free expression reactions, arXiv 2021, artificial cell myTXTL
Daicel Arbor Biosciences, a division of Daicel Chiral Technologies, and leader in developing molecular biology research tools, is pleased to introduce Ravindra Ramadhar as its new President.
Previously Mr. Ramadhar was Director, Strategy & Business Development within Thermo Fisher Scientific’s Genetics Science Division. Ramadhar brings a vast technical background to Daicel Arbor Biosciences with his prior experience as a director in the life and genetic sciences sectors, specifically focusing on applied markets in Agribusiness. His leadership will positively impact Daicel Arbor’s vision, strategy and portfolio development.
Mr. Ramadhar earned a Master of Business Administration (M.B.A.) from Whitman School of Management, Syracuse University, and Bachelor of Science from Rutgers University. He also received many hours of executive education from various programs at Harvard University.
With the addition of Mr. Ramadhar to the team, Daicel Arbor’s current President, Joseph M. Barendt, Ph.D., will continue to serve as President of Daicel Chiral Technologies and shift his attention to strategic growth projects within the newly formed Life Sciences Business area of Daicel Group. “I am excited to add someone of Mr. Ramadhar’s depth of experience, enthusiasm and leadership skills to the Daicel Arbor team and look forward to working closely with him over the coming years.”
Ramadhar adds “Daicel Arbor Biosciences’ extensive capabilities in genomics and tools for synthetic biology coupled with its passion for science provide a strong foundation for growth. Daicel Arbor Biosciences’ solutions enable genomics and synthetic biology researchers to answer key biological questions, advancing their research goals.”
SARS-CoV-2 research tools for academic, industry, public health, and surveillance applications. More info here.
Ann Arbor, MI 48103
(d/b/a Daicel Arbor Biosciences)
All Rights Reserved.